Chase Medical
Founded Year
1995Stage
Series D | DeadTotal Raised
$17.1MLast Raised
$8.1MAbout Chase Medical
Chase Medical is developing medical technology for treating congestive heart failure. Chase Medical is developing a device called the Mannequin which aims to help the heart maintain its shape while going through reconstruction of the left ventricle.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Chase Medical Patents
Chase Medical has filed 6 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/15/2004 | 8/10/2010 | Health informatics, Electronic health records, Telehealth, Pseudoscience, Health standards | Grant |
Application Date | 3/15/2004 |
|---|---|
Grant Date | 8/10/2010 |
Title | |
Related Topics | Health informatics, Electronic health records, Telehealth, Pseudoscience, Health standards |
Status | Grant |
Chase Medical Frequently Asked Questions (FAQ)
When was Chase Medical founded?
Chase Medical was founded in 1995.
Where is Chase Medical's headquarters?
Chase Medical's headquarters is located at 1876 Firman Drive, Richardson.
What is Chase Medical's latest funding round?
Chase Medical's latest funding round is Series D.
How much did Chase Medical raise?
Chase Medical raised a total of $17.1M.
Who are the investors of Chase Medical?
Investors of Chase Medical include Capital Southwest, First Capital Group and Red River Ventures.
Who are Chase Medical's competitors?
Competitors of Chase Medical include Respicardia, Cayenne Medical, CardioKinetix, CircuLite, MiCardia and 13 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Chase Medical to Competitors
Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure
CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.
Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.
CardioMetrix is a medical device company developing implantable technologies to assist physicians in managing patients suffering from congestive heart failure (CHF).
JenaValve develops, manufactures, and markets transcatheter aortic valve implantation systems (TAVI) to treat patients suffering from aortic valve disease. The company's transapical aortic valve system is CE-marked and currently marketed in Europe and other markets worldwide. The company was founded in 2006 and is based in Irvine, California.
Cardiac Dimensions develops minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. Its initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. The company was founded in 2000 and is based in Kirkland, Washington.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
